LFT

Medicenna Presents Updated Results of Single Agent MDNA11 Anti-tumor Activity from Dose Escalation and Ongoing Dose Expansion of the Phase 1/2 ABILITY-1 Study at the 2024 Annual Meeting of the American Association for Cancer Research (AACR)

Retrieved on: 
Wednesday, April 10, 2024
Hypertelorism, DLT, Safety, Radiation, Pancreatic cancer, TSX, PR, Cancer, LFT, Regulatory T cell, Patient, MDNA, RDE, Duodenal cancer, Toxicity, Melanoma, BCC, MCC, AACR, VLS, MSI-H, PD, NK, Combination therapy, Pharmaceutical industry

March 22, 2024) include:

Key Points: 
  • March 22, 2024) include:
    Acceptable safety profile: No dose limiting toxicity (DLT) reported and no evidence of vascular leak syndrome (VLS).
  • A new lymph node lesion developed during a 8-week MDNA11 treatment break (vacation) was treated with a single course of radiotherapy prior to resumption of MDNA11.
  • A new lymph node lesion developed at week 16 while baseline target and non-target lesions remained stable or decreased.
  • Monotherapy expansion is continuing to enroll patients with metastatic melanoma, non-melanoma skin cancers (cSCC, MCC, and BCC) and MSI-H/dMMR tumors.

Medicenna Presents Updated Results of Single Agent MDNA11 Anti-tumor Activity from Dose Escalation and Ongoing Dose Expansion of the Phase 1/2 ABILITY-1 Study at the 2024 Annual Meeting of the American Association for Cancer Research (AACR)

Retrieved on: 
Tuesday, April 9, 2024
Toxicity, PR, Combination therapy, VLS, MSI-H, PD, LFT, RDE, Duodenal cancer, Patient, Hypertelorism, Radiation, MCC, MDNA, AACR, TSX, DLT, Pancreatic cancer, Safety, Regulatory T cell, Melanoma, Cancer, BCC, NK, Pharmaceutical industry

March 22, 2024) include:

Key Points: 
  • March 22, 2024) include:
    Acceptable safety profile: No dose limiting toxicity (DLT) reported and no evidence of vascular leak syndrome (VLS).
  • A new lymph node lesion developed during a 8-week MDNA11 treatment break (vacation) was treated with a single course of radiotherapy prior to resumption of MDNA11.
  • A new lymph node lesion developed at week 16 while baseline target and non-target lesions remained stable or decreased.
  • Monotherapy expansion is continuing to enroll patients with metastatic melanoma, non-melanoma skin cancers (cSCC, MCC, and BCC) and MSI-H/dMMR tumors.

Lument Finance Trust Announces Year-End Earnings Release and Investor Call Dates

Retrieved on: 
Tuesday, March 12, 2024
LFT, Telephone, Webcast, URL, Annual report, Security (finance)

The conference call may be accessed by dialing 1-800-836-8184 (U.S.) or 1-646-357-8785 (international).

Key Points: 
  • The conference call may be accessed by dialing 1-800-836-8184 (U.S.) or 1-646-357-8785 (international).
  • Note: there is no passcode; please ask the operator to be joined into the Lument Finance Trust call.
  • A live webcast, on a listen-only basis, is also available and can be accessed through the URL:
    For those unable to listen to the live broadcast, a recorded replay will be available for on-demand viewing approximately one hour after the end of the event through the company's website https://lumentfinancetrust.com/ and by telephone dial-in.
  • The replay call-in number is 1-888-660-6345 (U.S.) or 1-646-517-4150 (international) with passcode 19268.

Sangamo Therapeutics Announces Updated Phase 1/2 STAAR Study Data in Fabry Disease Showing Sustained Benefit and Differentiated Safety Profile

Retrieved on: 
Monday, February 5, 2024
Pharmaceutical, Genetics, Health, Clinical Trials, Partnership, COVID-19, Steroid, Trial of the century, ERT, LFT, Pharmacology, Patient, Safety, FDA, Antibody, Glomerular filtration rate, Investment, Common, Fatigue, Fabry disease, Neutralizing antibody, Physical, STAAR, Therapy, Quality of life, Kidney, Headache, EGFR, Sangamo Therapeutics, Plasma, Form, Pharmaceutical industry

Sangamo Therapeutics, Inc. (Nasdaq: SGMO), a genomic medicine company, today announced updated preliminary data from the Phase 1/2 STAAR clinical study evaluating isaralgagene civaparvovec, or ST-920, a wholly owned gene therapy product candidate for the treatment of Fabry disease.

Key Points: 
  • Sangamo Therapeutics, Inc. (Nasdaq: SGMO), a genomic medicine company, today announced updated preliminary data from the Phase 1/2 STAAR clinical study evaluating isaralgagene civaparvovec, or ST-920, a wholly owned gene therapy product candidate for the treatment of Fabry disease.
  • “Despite the availability of ERT and chaperone therapies, Fabry disease treatment is burdensome, with some patients still developing disease progression.
  • The most common adverse events were pyrexia, headache, COVID-19, fatigue and nasopharyngitis (majority Grade 1/2, with one Grade 3 pyrexia).
  • The data demonstrated supraphysiological plasma and liver α-Gal A activity in mouse models, supporting Phase 1/2 and potential Phase 3 clinical dosing.

Advanced Lateral Flow Conference 2024 Innovation Award Finalists Announced

Retrieved on: 
Tuesday, January 16, 2024
Collection, SAN, Education minister, The Economist, Saliva, Hard Rock Cafe, Immunology, Conference, Compact, Creativity, LFT, Cell therapy

SAN DIEGO, Jan. 16, 2024 /PRNewswire/ -- DCN Dx, a global leader in the end-to-end development, manufacturing, and commercialization of point-of-use tests, has announced the finalists for its 2024 Innovation Awards.

Key Points: 
  • SAN DIEGO, Jan. 16, 2024 /PRNewswire/ -- DCN Dx, a global leader in the end-to-end development, manufacturing, and commercialization of point-of-use tests, has announced the finalists for its 2024 Innovation Awards.
  • The awards will be presented at the Advanced Lateral Flow Conference (ALFC) 2024.
  • Innovation Award finalists will pitch their entries to the ALFC audience on the first day of the event (Feb. 13, 2024).
  • For more information about the Advanced Lateral Flow Conference, visit alfc2024.com.

Medicenna Announces Promising Single-Agent Response and Durability of MDNA11 in the Phase 1/2 ABILITY Study During Dose Escalation at the 38th Annual Meeting of the Society for Immunotherapy of Cancer (SITC)

Retrieved on: 
Monday, November 6, 2023
Hypertelorism, PD, VLS, Trae tha Truth, BCC, MSI-H, MDNA, MCC, Poster, Pharmacodynamics, SITC, Immunotherapy, Radiation, SD, RDE, PK, DLT, Safety, Society, CSCC, PDAC, Patient, Combination therapy, Toxicity, TSX, LFT, Nevus, Medical imaging, Pharmaceutical industry, Vaccine

MDNA11 with uniquely differentiating ‘beta-enhanced not-alpha’ features, continues to be a potential best-in-class next-generation IL-2 super-agonist for treatment of advanced solid tumors.

Key Points: 
  • MDNA11 with uniquely differentiating ‘beta-enhanced not-alpha’ features, continues to be a potential best-in-class next-generation IL-2 super-agonist for treatment of advanced solid tumors.
  • Following return from a 7 week vacation, a single new lesion was observed and MDNA11 treatment was resumed.
  • Monotherapy expansion part of ABILITY-1 is enrolling patients with metastatic melanoma, non-melanoma skin cancers (CSCC, MCC, and BCC) and MSI-H/dMMR tumors.
  • A copy of the poster and a related slide deck have been posted to the “ Events and Presentations ” page of Medicenna’s website.

Lument Finance Trust Announces Quarter-End Earnings Release and Investor Call Dates

Retrieved on: 
Thursday, August 3, 2023
Telephone, Webcast, LFT, Security (finance), URL, NYSE

The conference call may be accessed by dialing 1-888-336-7151 (U.S.) or 1-412-902-4251 (international).

Key Points: 
  • The conference call may be accessed by dialing 1-888-336-7151 (U.S.) or 1-412-902-4251 (international).
  • Note: there is no passcode; please ask the operator to be joined into the Lument Finance Trust call.
  • A live webcast, on a listen-only basis, is also available and can be accessed through the URL:
    For those unable to listen to the live broadcast, a recorded replay will be available for on-demand viewing approximately one hour after the end of the event through the company's website https://lumentfinancetrust.com/ and by telephone dial-in.
  • The replay call-in number is 1-877-344-7529 (U.S.) or 1-412-317-0088 (international) with passcode 6083439.

OKX and Lifeform Launch Season 5 of Cryptopedia with Learn-to-Earn Prize Pool of USD300,000 in Lifeform Tokens for Over 11,000 Users

Retrieved on: 
Thursday, August 3, 2023
Ethereum, NFT, Web3, Decentralized application, LFT, Decentralized finance, OKX, UTC, Conflux, DEX, Cryptocurrency, Dapp, Outline of life forms, Polygon, Uniswap, Fantom, Optimism, Discover

Over 11,000 winners who have completed five online 'OKX quests' - DEX, NFT, DeFi, Discover and Lifeform - using OKX Wallet during Cryptopedia Season 5 from August 3, 2023 at 04:00 (UTC) to August 17, 2023 at 04:00 (UTC) will be selected to share in the prize pool.

Key Points: 
  • Over 11,000 winners who have completed five online 'OKX quests' - DEX, NFT, DeFi, Discover and Lifeform - using OKX Wallet during Cryptopedia Season 5 from August 3, 2023 at 04:00 (UTC) to August 17, 2023 at 04:00 (UTC) will be selected to share in the prize pool.
  • The quests encourage users to use and learn about the wide range of DApps available on the OKX Wallet.
  • Rewards will be distributed as below:
    How to participate in Cryptopedia Season Five:
    Create a wallet or import an existing one.
  • Interaction should be made on one of the Ethereum, BNB Chain, OKTC, Arbitrum One, Optimism, Polygon, or Fantom networks

OKX and Lifeform Launch Season 5 of Cryptopedia with Learn-to-Earn Prize Pool of USD300,000 in Lifeform Tokens for Over 11,000 Users

Retrieved on: 
Thursday, August 3, 2023
Ethereum, NFT, Web3, Decentralized application, LFT, Decentralized finance, OKX, UTC, Conflux, DEX, Cryptocurrency, Dapp, Outline of life forms, Polygon, Uniswap, Fantom, Optimism, Discover

Over 11,000 winners who have completed five online 'OKX quests' - DEX, NFT, DeFi, Discover and Lifeform - using OKX Wallet during Cryptopedia Season 5 from August 3, 2023 at 04:00 (UTC) to August 17, 2023 at 04:00 (UTC) will be selected to share in the prize pool.

Key Points: 
  • Over 11,000 winners who have completed five online 'OKX quests' - DEX, NFT, DeFi, Discover and Lifeform - using OKX Wallet during Cryptopedia Season 5 from August 3, 2023 at 04:00 (UTC) to August 17, 2023 at 04:00 (UTC) will be selected to share in the prize pool.
  • The quests encourage users to use and learn about the wide range of DApps available on the OKX Wallet.
  • Rewards will be distributed as below:
    How to participate in Cryptopedia Season Five:
    Create a wallet or import an existing one.
  • Interaction should be made on one of the Ethereum, BNB Chain, OKTC, Arbitrum One, Optimism, Polygon, or Fantom networks

Introducing vLite™ Technology -- the Industry’s Lightest, Highest Performing Load Cell for Portable Applications

Retrieved on: 
Thursday, June 1, 2023
VPG, LFT, Software, Infant, Vishay Intertechnology, NYSE, Incubator, Bridge, Electric battery

Designed to meet a need for a lighter-weight alternative to standard load cells in the indoor legal-for-trade (LFT) market, this breakthrough design reduces load cell weight by approximately 50%, while maintaining the same best-in-class quality, accuracy and reliability of VPG Force Sensors' family of load cells.

Key Points: 
  • Designed to meet a need for a lighter-weight alternative to standard load cells in the indoor legal-for-trade (LFT) market, this breakthrough design reduces load cell weight by approximately 50%, while maintaining the same best-in-class quality, accuracy and reliability of VPG Force Sensors' family of load cells.
  • The combination of reduced weight and high performance of vLite enables machine manufacturers to better address the specifications of portable applications.
  • There are several vLite off-the-shelf load cell models currently available, which are exchangeable with equivalent load cells.
  • To learn more about our vLite technology and load cells see: vLite - VPG Force Sensors and follow us on LinkedIn .